BackBioNexus Gene Lab Overview

BioNexus Gene Lab Common Stock

Track BioNexus Gene Lab's common stock ($20M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$20.17M
↑ 16.40% YoYΔ $2.84M vs prior year quarter

Peer trimmed avg / median

Loading

BioNexus Gene Lab Common Stock History

Loading

BioNexus Gene Lab vs. peers: Common Stock Comparison

Loading

BioNexus Gene Lab Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

BioNexus Gene Lab (BGLC) FAQ

As of the most recent data (June 2026), BGLC shows a common stock of $20M. That compares with $17M in the prior-year period — up 16.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BGLC's common stock is now $20M (was $17M) — a 16.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BioNexus Gene Lab is outperforming or lagging.

Tracking BGLC's common stock over time shows whether BioNexus Gene Lab is scaling, shrinking, or reshaping that part of the business. The current reading is $20M That compares with $17M in the prior-year period — up 16.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has BioNexus Gene Lab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $20M) with ownership activity and broader fundamentals.